The coronavirus pandemic has come as an opportunity for many companies and one of those in the life sciences outfit Revive Therapeutics (OTCMKTS: RVVTF). Yesterday, the Revive stock was in focus in the markets after the company announced an update with regards to the Phase 3 clinical trial of its COVID 19 medicine Bucillamine.
The trial in question is aimed at establishing the effectiveness and safety of the product on patients suffering from mild to moderate symptoms of COVID 19.
In addition to that, the company also revealed that it is on track with regard to its enrolment targets meant for the Independent Data and Safety Monitoring Board. The board is going to go through the data of as many as 210 patents that had been part of the interim analysis.
This is a significant milestone for the company and especially so at a time when the number of COVID 19 cases are rising again. Investors could consider keeping their eyes peeled regarding further updates from Revive.
Finance and Tech Contributor